Clinical Trials Browser

Active not recruiting × Ganglioneuroblastoma × Colony-Stimulating Factors × Clear all

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2 Active not recruiting

41 enrolled 13 charts

Neuroblastoma, Ganglioneuroblastoma